Hyaluronidase是一种能水解透明质酸的酶，Hyaluronidase可通过水解透明质酸来降低组织粘度并增加组织通透性。
Cas No.:37326-33-3;9001-54-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Hyaluronidase is an enzyme that hydrolyzes hyaluronic acid. Hyaluronidase can reduce tissue viscosity and increase tissue permeability through the hydrolysis of hyaluronic acid. Hyaluronidase is used in research related to drug diffusion assistance and the management of complications in medical aesthetics[1-4].
In vitro, Hyaluronidase (400μg/ml) was used to treat 3T3L1 adipocyte cell lines and mouse primary preadipocytes (from subcutaneous, visceral, or brown adipose tissue) for 8 days. Hyaluronidase significantly inhibited adipocyte differentiation and reduced lipid accumulation[5]. Hyaluronidase (400μg/ml) was applied to LiSa-2 liposarcoma cells for 24 hours. Hyaluronidase significantly increased cellular glucose uptake and lactate production, while enhancing plasma membrane GLUT1 localization and reducing TXNIP levels[6].
In vivo, Hyaluronidase (1U; 10μl) was administered via stereotactic intracranial injection in a controlled cortical impact traumatic brain injury model using C57BL/6J mice. Hyaluronidase significantly reduced brain edema after traumatic brain injury[7]. Hyaluronidase (12mg/kg) was intravenously injected into C57BL/6 mice for 30 minutes. Hyaluronidase significantly decreased the thickness of the retinal arteriolar glycocalyx and increased retinal microvascular permeability[8].
References:
[1] Yuan J, Hou B, Guo K, et al. Tumor-derived exosomal hyaluronidase 1 induced M2 macrophage polarization and promoted esophageal cancer progression. Exp Cell Res. 2024 Jun 1;439(1):113963.
[2] Shakouri A, Parvan R, Adljouy N, et al. Purification of hyaluronidase as an anticancer agent inhibiting CD44. Biomed Chromatogr. 2020 Jan;34(1):e4709.
[3] Tolwinski NS, Kano-Sueoka T. Hyaluronidase generates a single-cell suspension from cultured mouse lung epithelial cells. Biotechniques. 1997 May;22(5):856-8, 860.
[4] Meuwese MC, Broekhuizen LN, Kuikhoven M, et al. Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein E-deficient mice. PLoS One. 2010 Dec 8;5(12):e14262.
[5] Drygalski K, Higos R, Merabtene F, et al. Extracellular matrix hyaluronan modulates fat cell differentiation and primary cilia dynamics. Biochim Biophys Acta Mol Cell Biol Lipids. 2024 May;1869(4):159470.
[6] Sullivan WJ, Mullen PJ, Schmid EW, et al. Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization. Cell. 2018 Sep 20;175(1):117-132.e21.
[7] Washington PM, Lee C, Dwyer MKR, et al. Hyaluronidase reduced edema after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2020 Oct;40(10):2026-2037.
[8] Leskova W, Pickett H, Eshaq RS, et al. Effect of diabetes and hyaluronidase on the retinal endothelial glycocalyx in mice. Exp Eye Res. 2019 Feb;179:125-131.
Hyaluronidase是一种能水解透明质酸的酶，Hyaluronidase可通过水解透明质酸来降低组织粘度并增加组织通透性。Hyaluronidase可用于药物扩散辅助和医美并发症处理的相关研究[1-4]。
在体外，Hyaluronidase（400μg/ml）处理3T3L1脂肪细胞系、小鼠原代前脂肪细胞（来自皮下、内脏或棕色脂肪组织）8天。Hyaluronidase显著抑制脂肪细胞分化，减少脂质积累[5]。Hyaluronidase（400μg/ml）处理LiSa-2脂肪肉瘤细胞24小时。Hyaluronidase显著增加细胞的葡萄糖摄取和乳酸产生，同时增加质膜GLUT1定位并降低TXNIP水平[6]。
在体内，Hyaluronidase（1U；10μl）通过立体定位颅内注射于控制性皮质撞击创伤性脑损伤模型C57BL/6J小鼠的。Hyaluronidase显著减少了创伤性脑损伤后的脑水肿[7]。Hyaluronidase（12mg/kg）静脉注射于C57BL/6小鼠30分钟。Hyaluronidase显著减少了视网膜小动脉糖萼的厚度，同时增加了视网膜微血管的通透性[8]。
| Cell experiment [1]: | |
Cell lines | LiSa-2 liposarcoma cells |
Preparation Method | LiSa-2 cells were treated with Hyaluronidase (400μg/ml). |
Reaction Conditions | 400μg/ml; 24h |
Applications | Hyaluronidase treatment triggered a robust increase in glycolysis, as measured by glucose uptake and lactate production. Hyaluronidase enriched GLUT1 at the plasma membrane and acutely reduced TXNIP levels. |
| Animal experiment [2]: | |
Animal models | 3 month-old male C57BL/6J mice |
Preparation Method | Mice were subjected to controlled cortical impact (CCI) traumatic brain injury. Sterile-filtered Hyaluronidase (1U) or vehicle (sterile PBS) was delivered 4min after CCI or sham injury via stereotaxic intracerebroventricular (ICV) injection. |
Dosage form | 1U in 10μl; intracerebroventricular injection; single injection |
Applications | Hyaluronidase reduced edema in the ipsilateral hippocampus at 24h after CCI compared to vehicle-treated CCI mice. Hyaluronidase reduced the percentage of hyperintense, edematous voxels in the ipsilateral hippocampus measured by T2-weighted magnetic resonance imaging. |
References: | |
| Cas No. | 37326-33-3;9001-54-1 | SDF | |
| 别名 | 透明质酸酶 | ||
| 分子式 | 分子量 | ||
| 溶解度 | Water : 100 mg/mL (Need ultrasonic) | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Biological Activity: >300u/mg Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet